Ahinoam Lev-Sagie

Prof. Dr. Ahinoam Lev-Sagie

Hebrew University of Jerusalem, Jerusalem, Southern, Israel
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALAhinoam Lev-Sagie
Ahinoam Lev-Sagie
DGDebra Goldman-Wohl
Debra Goldman-Wohl
YCYotam Cohen
Yotam Cohen
MDMally Dori-Bachash
Mally Dori-Bachash
ALAvner Leshem
Avner Leshem
Eran ElinavEran Elinav
Eran Elinav

21 February 2017 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
YTYona Tadir
Yona Tadir
AGAdrian Gaspar
Adrian Gaspar
ALAhinoam Lev-Sagie
Ahinoam Lev-Sagie
MAMacrene Alexiades
Macrene Alexiades
RARed Alinsod
Red Alinsod
JNJohn Stuart Nelson
John Stuart Nelson

1 March 2009 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
ALAhinoam Lev-Sagie
Ahinoam Lev-Sagie
DPDiana Prus
Diana Prus
ILIara M. Linhares
Iara M. Linhares
YLYuval Lavy
Yuval Lavy
WLWilliam J. Ledger
William J. Ledger
SWSteven S. Witkin
Steven S. Witkin

1 September 2015 in Clinical Obstetrics and Gynecology
Verified
Journal Article
Closed access
ALAhinoam Lev-Sagie
Ahinoam Lev-Sagie
Vulvovaginal atrophy is a common condition associated with decreased estrogenization of the vaginal tissue. Symptoms include vaginal dryness, irritation, itching, soreness, burning, dyspareunia, discharge, urinary frequency, and urgency. It can occur at any time in a woman's life cycle, although more commonly in the postmenopausal phase, during which the prevalence is approximately 50%. Despite the high prevalence and the substantial effect on quality of life, vulvovaginal atrophy often remains underreported and undertreated. This article aims to review the physiology, clinical presentation, assessment, and current recommendations for treatment, including aspects of effectiveness and safety of local vaginal estrogen therapies.

1 January 2022 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Open access
ALAhinoam Lev-Sagie
Ahinoam Lev-Sagie
FSfrancesco de seta
francesco de seta
HVHans Verstraelen
Hans Verstraelen
GVGary Ventolini
Gary Ventolini
RLRisa Lonnee-Hoffmann
Risa Lonnee-Hoffmann
PVPedro Vieira-Baptista
Pedro Vieira-Baptista
Objective: This series of articles, titled The Vaginal Microbiome (VMB), written on behalf of the International Society for the Study of Vulvovaginal Disease, aims to summarize the recent findings and understanding of the vaginal bacterial microbiota, mainly regarding areas relevant to clinicians specializing in vulvovaginal disorders. Materials and Methods: A search of PubMed database was performed, using the search terms “vaginal microbiome” with “dysbiosis,” “bacterial vaginosis,” “cytolytic vaginosis,” “desquamative inflammatory vaginitis,” and “aerobic vaginitis.” Full article texts were reviewed. Reference lists were screened for additional articles. Results: The second article in this series focuses on vaginal dysbiotic conditions. Dysbiosis is a term describing imbalances in bacterial communities. Given that lactobacillus-dominated microbiota are thought to be the most optimal, vaginal dysbiosis is usually considered as lactobacilli-depleted VMB. Bacterial vaginosis (BV), the most common vaginal dysbiotic condition, is a polymicrobial disorder, considered the leading cause for vaginal discharge in women worldwide. In addition, we review the VMB in other vaginal conditions associated with lactobacilli depletion: desquamative inflammatory vaginitis and aerobic vaginitis. We also discuss the controversial diagnosis of cytolytic vaginosis, related with lactobacilli overgrowth. Conclusions: Bacterial vaginosis displays complex microbiology. The heterogeneity and diversity within the genus Gardnerella may impact the progression of BV. Bacterial biofilms may contribute to the etiology and persistence of BV, and various bacteria may affect its clinical presentation and pathogenicity. Lack of lactobacilli is not always accompanied by an overgrowth of anaerobes.

1 January 2022 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Open access
HVHans Verstraelen
Hans Verstraelen
PVPedro Vieira-Baptista
Pedro Vieira-Baptista
FSfrancesco de seta
francesco de seta
GVGary Ventolini
Gary Ventolini
RLRisa Lonnee-Hoffmann
Risa Lonnee-Hoffmann
ALAhinoam Lev-Sagie
Ahinoam Lev-Sagie
Objective: This series of articles, titled The Vaginal Microbiome, written on behalf of the International Society for the Study of Vulvovaginal Disease, aims to summarize the current findings and understanding of the vaginal bacterial microbiota, mainly regarding areas relevant to clinicians specializing in vulvovaginal disorders. Materials and Methods: A database search of PubMed was performed, using the search terms “vaginal microbiome” (VMB) with “research,” “normal,” “neonate,” “puberty,” “adolescent,” “menopause,” and “ethnicities,” as well as “human microbiome project.” Full article texts were reviewed. Reference lists were screened for additional articles. Results: In the last 2 decades, many studies applying molecular techniques were performed, intending to characterize the vaginal microbiota. These studies advanced our understanding of how vaginal health is defined. The first article in this series focuses on the advancement of VMB research, technical definitions, the definition of “normal” VMB, and the dynamics of VMB throughout women's lives. Conclusions: Understanding how microorganisms inhabiting the vagina interact with each other and with the host is important for a more complete understanding of vaginal health. The clinical application of microbial community sequencing is in its beginning, and its interpretation regarding practical clinical aspects is yet to be determined.